Tag Archive for: DelSiTech™ Silica Matrix technology

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

/in

Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company […]

Read more

DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

/in

Turku, Finland – 28 March 2022: – DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Optifye Therapeutics AG, a Swiss-based pharmaceutical company focusing on the development and commercialization of treatments for ophthalmic indications, today announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech™ Silica Matrix technology. Read more…

Read more